Fármacos antiangiogénicos y piel: efectos cutáneos adversos de sorafenib, sunitinib y bevacizumab

Chu, 2008, Risk of hand-foot skin reaction with sorafenib: A systematic review and meta-analysis, Acta Oncol, 47, 176, 10.1080/02841860701765675 Goldman, 1907, The growth of malignant disease in man and the lower animals with special reference to the vascular system, Lancet, 2, 1236, 10.1016/S0140-6736(01)65002-5 Greenblatt, 1968, Tumor angiogenesis: Transfilter diffusion studies in the hamster by the transparent chamber technique, J Natl Cancer Inst, 41, 111 Ehrmann, 1968, Choriocarcinoma: Transfilter stimulation of vasoproliferation in the hamster cheek pouch studied by light and electron microscopy, J Natl Cancer Inst, 41, 1329 Folkman, 1971, Tumor angiogenesis: Therapeutic implications, N Engl J Med, 285, 1182, 10.1056/NEJM197111182852108 Lacouture, 2008, Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib, Oncologist, 13, 1001, 10.1634/theoncologist.2008-0131 Lee, 2009, Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib, Br J Dermatol, 161, 1045, 10.1111/j.1365-2133.2009.09290.x Battistella, 2010, Sunitinib efficacy in the treatment of metastatic skin adnexal carcinomas: Report of two patients with hidradenocarcinoma and trichoblastic carcinoma, J Eur Acad Dermatol Venereol, 24, 199, 10.1111/j.1468-3083.2009.03301.x Wozel, 2010, Cutaneous side effects of inhibition of VEGF signal transduction, J Dtsch Dermatol Ges, 8, 243, 10.1111/j.1610-0387.2009.07268_supp.x Braghioli, 2012, Bevacizumab: Overview of the literature, Expert Rev Anticancer Ther, 12, 567, 10.1586/era.12.13 McLellan, 2011, Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib, Dermatol Therap, 24, 396, 10.1111/j.1529-8019.2011.01435.x Zhang, 2011, Meta-analysis of dermatological toxicities associated with sorafenib, Clin Exp Dermatol, 36, 344, 10.1111/j.1365-2230.2011.04060.x Autier, 2008, Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor, Arch Dermatol, 144, 886, 10.1001/archderm.144.7.886 Robert, 2009, Dermatologic symptoms associated with the multikinase inhibitor sorafenib, J Am Acad Dermatol, 60, 299, 10.1016/j.jaad.2008.06.034 Kong, 2009, Array of cutaneous adverse effects associated with sorafenib, J Am Acad Dermatol, 61, 360, 10.1016/j.jaad.2009.02.004 Lipworth, 2009, Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): Focus on sorafenib and sunitinib, Oncology, 77, 257, 10.1159/000258880 Nardone, 2010, The effect of hand-foot skin reaction associated with the multikinase inhibitors sorafenib and sunitinib on health-related quality of life, J Drugs Dermatol, 11, e61 Yang, 2008, Hand-foot skin reaction in patients treated with sorafenib: A clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy, Br J Dermatol, 158, 592, 10.1111/j.1365-2133.2007.08357.x Jain, 2010, Lack of association between excretion of sorafenib in sweat and hand-foot skin reaction, Pharmacotherapy, 30, 52, 10.1592/phco.30.1.52 Sibaud, 2009, Sorafenib-induced hand-foot skin reaction: A Koebner phenomenon, Target Oncol, 4, 307, 10.1007/s11523-009-0127-8 Lee, 2013, Genetic predisposition of hand-foot skin reaction after sorafenib therapy in patients with hepatocellular carcinoma, Cancer, 119, 136, 10.1002/cncr.27705 Dranitsaris, 2012, Development and validation of a prediction index for hand-foot skin reaction in cancer patients receiving sorafenib, Ann Oncol, 23, 2103, 10.1093/annonc/mdr580 Anderson, 2009, Search for evidence-based approaches for the prevention and palliation of hand-foot skin reaction (HFSR) caused by multikinase inhibitors (MKIs), Oncologist, 14, 291, 10.1634/theoncologist.2008-0237 National Cancer Institute, Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events v4.03 (CTCAE). [consultado 6 Ago2013]. Disponible en: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5(11.pdf Robert, 2005, Cutaneous side-effects of kinase inhibitors and blocking antibodies, Lancet Oncol, 6, 491, 10.1016/S1470-2045(05)70243-6 Arnault, 2009, Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib, J Clin Oncol, 27, e59, 10.1200/JCO.2009.23.4823 Kong, 2007, Keratoacanthomas associated with sorafenib therapy, J Am Acad Dermatol, 56, 171, 10.1016/j.jaad.2006.10.032 Williams, 2011, Sorafenib-induced premalignant and malignant skin lesions, Int J Dermatol, 50, 396, 10.1111/j.1365-4632.2010.04822.x Arnault, 2012, Skin tumors induced by sorafenib: Paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53 and TGFBR1, Clin Cancer Res, 18, 263, 10.1158/1078-0432.CCR-11-1344 Robert, 2011, RAF inhibition and induction of cutaneous squamous cell carcinoma, Curr Opin Oncol, 23, 177, 10.1097/CCO.0b013e3283436e8c Kobayashi, 1996, Keratoacanthomas and skin neoplasms associated with suramin therapy, Arch Dermatol, 132, 96, 10.1001/archderm.132.1.96 Su, 2012, RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors, N Engl J Med, 366, 207, 10.1056/NEJMoa1105358 Oberholzer, 2012, RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors, J Clin Oncol, 30, 316, 10.1200/JCO.2011.36.7680 Chu, 2012, Diverse cutaneous side effects associated with BRAF inhibitor therapy: A clinicopathologic study, J Am Acad Dermatol, 67, 1265, 10.1016/j.jaad.2012.04.008 Kong, 2008, Sorafenib-induced eruptive melanocytic lesions, Arch Dermatol, 144, 820, 10.1001/archderm.144.6.820 Bennani-Lahlou, 2008, Eruptive nevi associated with sorafenib treatment, Ann Dermatol Venereol, 135, 672, 10.1016/j.annder.2008.04.016 Dalle, 2011, Vemurafenib in melanoma with BRAF V600E mutation, N Engl J Med, 365, 1448, 10.1056/NEJMc1108651 Zimmer, 2012, Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition, J Clin Oncol, 30, 2375, 10.1200/JCO.2011.41.1660 Lopez, 2009, Follicular hyperplasia on the face subsequent to therapy with sorafenib. A new skin side effect, J Eur Acad Dermatol Venereol, 23, 959, 10.1111/j.1468-3083.2008.03003.x Franck, 2010, Spiny follicular hyperkeratosis eruption: A new cutaneous adverse effect of sorafenib, J Clin Oncol, 28, e640, 10.1200/JCO.2010.31.3783 Joncas, 2008, A distinct cutaneous reaction to sorafenib and a multikinase inhibitor, Int J Dermatol, 47, 767, 10.1111/j.1365-4632.2008.03598.x Haycox, 1999, Trichodysplasia spinulosa—a newly described folliculocentric viral infection in an immunocompromised host, J Investig Dermatol Symp Proc, 4, 268, 10.1038/sj.jidsp.5640227 Sadler, 2007, Trichodysplasia spinulosa associated with chemotherapy for acute lymphocytic leukaemia, Australas J Dermatol, 48, 110, 10.1111/j.1440-0960.2007.00348.x Lee, 2008, Progressive trichodysplasia spinulosa in a patient with chronic lymphocytic leukaemia in remission, Australas J Dermatol, 49, 57, 10.1111/j.1440-0960.2007.00422.x Schwieger-Briel, 2010, Trichodysplasia spinulosa—a rare complication in immunosuppressed patients, Pediatr Dermatol, 27, 509, 10.1111/j.1525-1470.2010.01278.x Fischer, 2012, Specific detection of trichodysplasia spinulosa-associated polyomavirus DNA in skin and renal allograft tissues in a patient with trichodysplasia spinulosa, Arch Dermatol, 148, 726, 10.1001/archdermatol.2011.3298 van der Meijden, 2010, Discovery of a new human polyomavirus associated with trichodysplasia spinulosa in an immunocompromized patient, PloS Pathog, 6, e1001024, 10.1371/journal.ppat.1001024 Elaba, 2012, Ultrastructural and molecular confirmation of the trichodysplasia spinulosa-associated polyomavirus in biopsies of patients with trichodysplasia spinulosa, J Cutan Pathol, 39, 1004, 10.1111/j.1600-0560.2012.01972.x Dasanu, 2007, Yellow skin discoloration associated with sorafenib use for treatment of metastatic renal cell carcinoma, South Med J, 100, 328, 10.1097/SMJ.0b013e31802f01a9 Richetta, 2007, Sorafenib: Atypical cutaneous side effects, Eur J Dermatol, 17, 549 Rübsam, 2011, Erythema marginatum hemorrhagicum: A unique cutaneous side effect of sorafenib, J Am Acad Dermatol, 64, 1194, 10.1016/j.jaad.2009.08.035 Rodríguez-Vázquez, 2010, Atypical linear toxicodermia by sorafenib, Int J Dermatol, 49, 1214, 10.1111/j.1365-4632.2010.04518.x Diamantis, 2010, Sorafenib-induced psoriasiform eruption in a patient with metastatic thyroid carcinoma, J Drugs Dermatol, 9, 169 Laquer, 2010, Sorafenib-associated psoriasiform skin changes, Cutis, 85, 301 González-Lopez, 2011, Psoriasiform skin eruption associated with sorafenib therapy, Indian J Dermatol Venereol Leprol, 77, 614, 10.4103/0378-6323.84089 Namba, 2011, Sorafenib-induced erythema multiforme: Three cases, Eur J Dermatol, 21, 1015, 10.1684/ejd.2011.1535 Rosenbaum, 2008, Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib, Support Care Cancer, 16, 557, 10.1007/s00520-008-0409-1 Boone, 2009, Blackberry-induced hand-foot skin reaction to sunitinib, Invest New Drugs, 27, 389, 10.1007/s10637-008-9196-2 Tsai, 2006, Hand-foot syndrome and seborrheic dermatitis-like rash induced by sunitinib in a patient with advanced renal cell carcinoma, J Clin Oncol, 24, 5786, 10.1200/JCO.2006.08.6868 Poprach, 2012, Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: A national registry-base study, Ann Oncol, 23, 3137, 10.1093/annonc/mds145 Narayanan, 2010, Improvement of psoriasis during sunitinib therapy for renal cell carcinoma, Am J Med Sci, 339, 580, 10.1097/MAJ.0b013e3181dd1aa5 Elias, 2008, Epidermal vascular endothelial growth factor production is required for permeability barrier homeostasis, dermal angiogenesis, and the development of epidermal hyperplasia: Implications for the pathogenesis of psoriasis, Am J Pathol, 172, 689, 10.2353/ajpath.2008.080088 Wollenberg, 2010, Cutaneous side effects of the multikinase inhibitors sorafenib and sunitinib, Hautarzt, 61, 662, 10.1007/s00105-010-1942-7 Hartmann, 2008, Sunitinib an periodic hair depigmentation due to temporary c-KIT inhibition, Arch Dermatol, 144, 1525, 10.1001/archderm.144.11.1525 Billemont, 2008, Scrotal cutaneous side effects of sunitinib, N Engl J Med, 359, 975, 10.1056/NEJMc0802736 Iacovelli, 2012, Genital and inguinal toxicity in male and female patients treated with sunitinib, Int J Dermatol, 51, 221, 10.1111/j.1365-4632.2011.05057.x Vignand-Courtin, 2012, Cutaneous side effects associated with sunitinib: An analysis of 8 cases, Int J Clin Pharm, 34, 286, 10.1007/s11096-012-9615-5 Tonini, 2010, Recurrent scrotal hemangiomas during treatment with sunitinib, J Clin Oncol, 28, e737, 10.1200/JCO.2010.30.4865 Chou, 2013, Sunitinib-induced scrotal cutaneous side-effect, J Dermatol, 40, 67, 10.1111/j.1346-8138.2012.01681.x Ritter, 2007, Pathogenesis of infantile hemangioma: New molecular and cellular insights, Expert Rev Mol Med, 9, 1, 10.1017/S146239940700052X Sibaud, 2011, Dermatologic side effects induced by new angiogenesis inhibitors, Bull Cancer, 98, 1221, 10.1684/bdc.2011.1457 Sheen, 2007, Eccrine squamous syringometaplasia associated with sunitinib therapy, JEADV, 21, 1136 Ten Freyhaus, 2008, Pyoderma gangrenosum: Another cutaneous side-effect of sunitinib, Br J Dermatol, 159, 242, 10.1111/j.1365-2133.2008.08599.x Nadauld, 2011, Pyoderma gangrenosum with the use of sunitinib, J Clin Oncol, 29, e266, 10.1200/JCO.2010.32.6165 Akanay-Diesel, 2011, Sunitinib induced pyoderma gangrenosum-like ulcerations, Eur J Med Res, 16, 491, 10.1186/2047-783X-16-11-491 Dean, 2010, A second case of sunitinib-associated pyoderma gangrenosum, J Clin Aesthetic Dermatol, 3, 34 Ueharaguchi, 2013, A case of pyoderma gangrenosum possibly associated with sunitinib treatment, Int J Dermatol, 52, 634, 10.1111/j.1365-4632.2011.04952.x Martorell-Calatayud, 2011, Gottron-like papules induced by sunitinib, Actas Dermosifiliogr, 102, 385, 10.1016/j.ad.2010.08.009 Kluger, 2011, Lower limbs erosions induced by sunitinib, Acta Derm Venereol, 91, 360, 10.2340/00015555-1016 Saif, 2008, Correlation between rash and a positive drug response associated with bevacizumab in a patient with advanced colorectal cancer, Clin Colorectal Cancer, 7, 144, 10.3816/CCC.2008.n.020 Gotlib, 2006, Skin rash secondary to bevacizumab in a patient with advanced colorectal cancer and relation to response, Anticancer Drugs, 17, 1227, 10.1097/01.cad.0000231481.07654.fc Ladas, 2009, Skin rash associated with intravitreal bevacizumab in a patient with macular choroidal neovascularization, Clin Ophthalmol, 3, 129 Ameselem, 2009, Papulopustular eruption after intravitreal bevacizumab (Avastin), Acta Ophthalmol, 87, 110, 10.1111/j.1755-3768.2007.01154.x Scappaticci, 2005, Surgical healing complications in metastatic colorectal cancer patients treated with bevacizumab, J Surg Oncol, 91, 173, 10.1002/jso.20301 Gordon, 2009, A review on bevacizumab and surgical wound healing: An important warning to all surgeons, Ann Plast Surg, 62, 707, 10.1097/SAP.0b013e3181828141 Christoforidis, 2013, The effect of intravitreal bevacizumab and ranibizumab on cutaneous tensile strength during wound healing, Clin Opthalmol, 7, 185, 10.2147/OPTH.S40537 Peters, 2011, Ulceration of striae distensae in high-grade glioma patients on concurrent systemic corticosteroid and bevacizumab therapy, J Neurooncol, 101, 155, 10.1007/s11060-010-0239-0 Fourcade, 2011, Localized skin necrosis of steroid-induced striae distensae: An unusual complication of bevacizumab and irinotecan therapy, Arch Dermatol, 147, 1227, 10.1001/archdermatol.2011.311 Wheeler, 2012, Dehiscence of corticosteroid-induced abdominal striae in a 14-year old boy treated with bevacizumab for recurrent glioblastoma, J Child Neurol, 27, 927, 10.1177/0883073811428007 Vano-Galvan, 2009, Perforating dermatosis in a patient receiving bevacizumab, J Eur Acad Dermatol Venereol, 23, 972, 10.1111/j.1468-3083.2008.03078.x